Thromboembolic events associated with antiangiogenic monoclonal antibodies: a disproportionality analysis from FDA adverse event reporting system (FAERS) database. [PDF]
Thromb JZhou H, Su Y, Song J, Zhen L.
europepmc +1 more source
Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies. [PDF]
Drug Des Devel TherTao Y, Zhang Y, Xu W, Liu G, Liu H.
europepmc +1 more source
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial. [PDF]
NPJ Precis OncolPu T +11 more
europepmc +1 more source
Short-term outcomes and choroidal morphological changes following aflibercept therapy in pachychoroid neovasculopathy. [PDF]
Sci RepKim JH +5 more
europepmc +1 more source
TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. [PDF]
Eye (Lond)Regillo C +6 more
europepmc +1 more source
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial. [PDF]
Jpn J OphthalmolSuzuma K +18 more
europepmc +1 more source
Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence. [PDF]
BMC OphthalmolOwlya N +7 more
europepmc +1 more source
Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. [PDF]
Invest Ophthalmol Vis SciKato N +6 more
europepmc +1 more source
Bilateral idiopathic peripapillary choroidal neovascularization in a child with bruton disease: a case report. [PDF]
BMC OphthalmolKerkouri S +6 more
europepmc +1 more source
Twelve-month lesion reactivation after initial loading injections of faricimab in neovascular AMD: a comparison between three and four loading injections. [PDF]
BMC OphthalmolHan HY, Park SM, Lee JH, Kim CG, Kim JH.
europepmc +1 more source